Stockreport

CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight Report 2026 - First CD276 Therapy Approval Anticipated by 2028 [Yahoo! Finance]

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF Key areas include antibody-drug conjugates, CAR T-cell treatments, and bispecific antibodies targeting difficult cancers. Strategic partnerships and platform innovations [Read more]